RESEARCH AND DEVELOPMENT ( R & D ) IS OFTEN THE MOST TIME- CONSUMING PART OF THE DRUG DEVELOPMENT PROCESS , BUT AI CAN ACCELERATE THIS PROCESS BY UP TO 50 %. and each company ’ s own research data in order to identify the patterns relevant to investigational products , certain conditions , specific patient populations , or other factors . As the Generative AI tool identifies relevant patterns , it can combine all the insights to design a baseline study , with a defined narrative that determines eligibility , drafts exclusionary criteria , and provides other necessary details . It can generate a number of draft options that would later be evaluated and refined by a human .
H E A L T H I N S I G H T S
capabilities can automate a substantial proportion of the protocol writing process , bringing it down to days or even mere hours .
Generative AI can be trained on thousands of existing protocols in industry databases
RESEARCH AND DEVELOPMENT ( R & D ) IS OFTEN THE MOST TIME- CONSUMING PART OF THE DRUG DEVELOPMENT PROCESS , BUT AI CAN ACCELERATE THIS PROCESS BY UP TO 50 %. and each company ’ s own research data in order to identify the patterns relevant to investigational products , certain conditions , specific patient populations , or other factors . As the Generative AI tool identifies relevant patterns , it can combine all the insights to design a baseline study , with a defined narrative that determines eligibility , drafts exclusionary criteria , and provides other necessary details . It can generate a number of draft options that would later be evaluated and refined by a human .
Expediting launch processes in secondary markets
Once a new therapy has been approved to launch in one market , many companies will be looking to expand the launch into
18 www . intelligenthealth . tech